Study Summary: EMERALD - AJMC.com Managed Markets Network

Study Summary: EMERALD
AJMC.com Managed Markets Network
Orkin C, Molina JM, Negredo E, et al; EMERALD Study Group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and ...